iiinova — where your digital self keeps evolving

Leila Agha

@leilaagha.bsky.social

179 followers 379 following 0 posts

Economist, Assoc Prof of Health Care Policy at Harvard

Posts Replies Media

Reposted by Leila Agha

NBER @nber.org · 29/09/2026

Guideline and physician performance in atrial fibrillation depend on how bleeding harms vary across patients; robust treatment rules can perform well across plausible harm assumptions, from @jabaluck, @LeilaEcon, and David C. Chan Jr www.nber.org/papers/w35798

153

Reposted by Leila Agha

NBER @nber.org · 20/03/2026

Featured in the latest Bulletin on Health: Selective Participation in Clinical Trials Biases Estimates of Side Effects www.nber.org/bh/20261/sel...

062

Reposted by Leila Agha

NBER @nber.org · 10/12/2025

Cancer-drug trials under enroll patients at high risk of serious adverse events and underestimate drug-induced harms. Regulating representativeness could improve external validity, from Jason Abaluck, @leilaagha.bsky.social, and Sachin Shah www.nber.org/papers/w34534

053

Reposted by Leila Agha

NBER @nber.org · 18/10/2025

Female pediatricians’ temporary absences lead to lasting cuts to kids’ care—fewer visits, vaccines, and lead tests—showing work disruptions carry consumer costs, from @leilaagha.bsky.social , Na'ama Shenhav, and Myles Wagner www.nber.org/papers/w34360

0106